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Ligand bindingInterfacing ion mobility spectrometry to mass spectrometry (IMS–MS) has enabled mass spectrometric analyses
to extend into an extra dimension, providing unrivalled separation and structural characterization of lowly
populated species in heterogeneous mixtures. One biological system that has beneﬁtted signiﬁcantly from such
advances is that of amyloid formation. Using IMS–MS, progress has been made into identifying transiently popu-
lated monomeric and oligomeric species for a number of different amyloid systems and has led to an enhanced
understanding of the mechanism by which small molecules modulate amyloid formation. This review highlights
recent advances in this ﬁeld, which have been accelerated by the commercial availability of IMS–MS instruments.
This article is part of a Special Issue entitled: Mass spectrometry in structural biology.
© 2012 Elsevier B.V. Open access under CC BY license.1. Introduction
Mass spectrometry (MS) has become widely accepted as a tool to
analyse biological systems over the past twenty years, subsequent to
the pioneering development of electrospray ionization (ESI) [1,2]. The
advent of ESI, and other soft ionization techniques such as matrix
assisted laser desorption ionization (MALDI) [3], initiated a new
ﬁeld in which a wealth of information about protein structure and
macromolecular assemblies can be deduced using MS, including
revealing insights about protein/ligand binding and dynamic struc-
ture. Whereas theﬁrst ESI–MSexperiments of biologicalmacromolecules
provided accurate molecular mass measurements [2], the technique
evolved rapidly such that structural information about proteins and
their biomolecular complexes could be obtained, in addition to informa-
tion about protein stability, dynamics and post-translational modiﬁca-
tions [4–12]. The use of ESI–MS in structural biology has been
acceleratedmost recently through the coupling of ionmobility spectrom-
etry (IMS) toMS [13–16]. This approach has enabled the detailed analysis
of biological systems, particularly in cases where alternative techniques
such as crystallography or nuclear magnetic resonance are unable to bectrospray ionization–mass spec-
ion mobility spectrometry–mass
pectrometry in structural
: +44 113 343 7486.
ord), A.E.Ashcroft@leeds.ac.uk
Y license.used due to the analyte's poor solubility, large mass, and/or the inability
to crystallize, or in cases where the species of interest are present within
a heterogeneous mixture [17]. In this review, we describe the principles
of mass spectrometry coupled with ion mobility spectrometry (IMS–
MS) and discuss how this approach has enhanced our understanding of
protein oligomerization during self-assembly into amyloid.2. Background to ESI–IMS–MS development and application to
biological systems
Ion mobility spectrometry (IMS) is able to separate complex mix-
tures of ions based on their shape and/or charge [18,19], yielding
structural information complementary to molecular mass measure-
ments. The technique of IMS relies on separating gaseous ions
according to their mobility through a drift-tube ﬁlled with a buffer
gas [18]. Ions are accelerated through the drift tube by an electric
ﬁeld, wherein ions of differing shapes have different mobilities
depending on an ion's characteristic collision cross-section (CCS).
Larger, extended ions will experience more collisions with the buffer
gas and, as a result, will take longer to traverse the drift tube in com-
parison with smaller, more compact ions of the same molecular mass
which will undergo fewer collisions with the buffer gas and hence
will have a greater mobility and a shorter drift time. One caveat to
ion mobility analysis is that the CCS data collected from ion mobility
analyses give a rotationally averaged value, as the gaseous ions are
able to collidewith the buffer gas in a number of different orientations.
Despite this, when used in conjunction with mass spectrometry, it has
been shown that structural features of proteins and protein complexes
can be elucidated [20,21].
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produced excellent results but has been limited to home-built instru-
mentation [16,22–24]. Over the past decade, much effort has been di-
rected at producing commercially viable instrumentation. This has
led to the development of ion mobility separation based on either a
differential IMS setup [25,26] or a travelling-wave IMS system
(Fig. 1) [15]. In particular, travelling-wave IMS–MS has been found
to be promising for protein analysis, showing good sensitivity and
separative power, and it can be used to measure the mass and to es-
timate CCS value for each individual component within a sample. Al-
though it is possible to acquire CCS values directly from drift-times
using conventional IMS [27], calibration of the travelling-wave IMS
device with ions of known CCS is required [28–30]. Once the
travelling-wave IMS device has been calibrated, CCSs can be estimat-
ed for previously uncharacterised species. In the case of a protein, a
CCS can be derived for each of its charge state ions. A folded,
native-like protein conformer may only give rise to two or three
charge state ions, all with similar CCSs; however, an unfolded protein
conformer could generate a wide charge state distribution, with the
higher charge state ions having much larger CCSs than the lower
charge state ions, a phenomenon due in part to Coulombic repulsions
between the charges of the highly charged ions. Therefore, for each
protein conformer, the CCS of the lowest charge state ions is usually
the smallest and therefore the one used to deﬁne that particular
conformer. Using this approach, IMS–MS has revealed valuable infor-
mation on a range of biological systems [31–34]. One area that has
beneﬁted greatly from such analyses is that in which transient inter-
mediate species are lowly populated and short lived, such as in
amyloid ﬁbril formation, as discussed below.Monomer
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Fig. 1. Schematic showing commercially available travelling-wave ion mobility spectrometr
spectrometer. Ions are separated in the TWIMS device based on their mobility through the d
the buffer gas molecules present in the drift cell and have a longer drift time than more comp
different charge, for example a mixture of protein oligomers including a monomer with one
number of charges. Typically, for a given m/z, the more highly charged ions have a shorter
Figure adapted from [15].3. Amyloidosis: a challenging biomolecular assembly system ideal
for analysis by ESI–IMS–MS
More than 25 different proteins or peptides, whose aggregation into
ﬁbrils is associated with amyloidosis in vivo, have been identiﬁed to
date [35]. In different amyloid disorders, ﬁbrils accumulate in speciﬁc
regions of the body causing the variety of symptoms associated with
individual diseases [36,37]. Due to the prevalence of these diseases,
gaining insights into how amyloid deposits form and how their pro-
duction can be halted is crucial. To achieve this, in vitro techniques
have been employed to provide information. The advantage of such
experiments is that amyloid formation can be induced to occur on rel-
atively rapid timescales, rather than the decades or more generally
required for amyloid to become symptomatic in vivo. Accordingly, de-
creasing the pH, incubating with protein denaturants such as sodium
dodecyl sulphate, exposing the protein or peptide to metal ions, intro-
ducing destabilising mutations into the protein sequence, and/or agi-
tating the solution vigorously have all been used to initiate rapid
ﬁbril formation in vitro [37–39]. The formation of amyloid-like ﬁbrils
under these conditions can be conﬁrmed using imaging methods such
as electron microscopy (Fig. 2a) or atomic force microscopy [35],
complemented by X-ray ﬁbre diffraction to conﬁrm the presence of
the well-characterized cross-β structure of amyloid (Fig. 2b) [37].
Additionally, small organic molecules known to bind to amyloid ﬁbrils
are commonly used to detect their presence: Congo red is particularly
useful in this role as upon excitation with plane-polarised light the
dye exhibits apple-green birefringence when bound to the regular
array of β-strands within the cross-β structure of amyloid [40]
(Fig. 2c, d). Thus, Congo red birefringence is an excellent diagnosticDrift time (ms)
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Fig. 2. Characterisation of in vitro β2-microglobulin (β2m) amyloid ﬁbril formation. (a) Electron microscopy image of long, straight β2m ﬁbrils (scale bar=100 nm); (b) X-ray ﬁbre
diffraction of long, straight β2m ﬁbrils showing the hallmark amyloid pattern; (c) Congo red staining and (d) Congo red birefringence of β2m ﬁbrils. (e) Schematic representation of ﬁbril
formation starting frommonomer (pink circles) and proceeding via dimers and higher-order oligomers (pink squares) along seeded and unseeded assembly pathways to produce ﬁbrils
of different morphologies.
Figure taken from T. J. Jahn, PhD Thesis, University of Leeds, 2006 [64].
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vivo. In addition, the dye thioﬂavin T is commonly used tomonitorﬁbril
formation both in vitro and in vivo, as a change in ﬂuorescence of this
molecule is experienced upon binding to ﬁbrils [41]. In in vitro experi-
ments, thioﬂavin T ﬂuorescence can be monitored in real-time during
protein aggregation to determine the kinetics of ﬁbril formation. Typical-
ly, ordered amyloid assembly proceeds via a nucleated assembly mecha-
nism [42,43], consisting of a lag-phase in which a critical nucleus forms,
followed by a growth phase and stationary phase (Fig. 2e). Identiﬁcation
of species in each of these phases is crucial for understanding the mech-
anism(s) of ﬁbril formation and for identifying potential targets for ligand
binding. The latter is especially important as such studies could pave the
way for the development of therapeutics to block ﬁbril formation and/or
control oligomer production with its associated toxicity.
Protein aggregation of an initially soluble protein monomer is
thought to be initiated by a misfolding or unfolding event, resulting
in one or more species capable of undergoing oligomerization. Next,
oligomers form and may either assemble directly into amyloid ﬁbrils
or, alternatively, undergo a structural rearrangement preceding ﬁbril
formation [44,45]. Identifying oligomeric species both on- and off-
pathway to ﬁbril formation is challenging, yet crucial to understand-
ing the molecular mechanisms of ﬁbrillogenesis. While using small
molecules to target on-pathway oligomeric species could lead to the
inhibition of ﬁbril formation, off-pathway oligomers are equally inter-
esting as in some cases they have been shown to exhibit toxicity
against numerous cell-lines [46,47]. It is for these reasons that
research into ﬁbril formation is divided between those who consideramyloid ﬁbrils to be the primary cause of the symptoms associated
with disease and those who consider the oligomers present during
ﬁbril formation, or alternatively formed by dissociation of ﬁbrils, to
be the causative agents of the disease [48–51]. Both such scenarios
could be involved, at least in some disorders. Therefore, it is essential
to identify all of the monomeric and oligomeric species present with-
in these heterogeneous mixtures, and to characterize their structures,
dynamic properties and ligand binding capabilities of each as much as
possible. It is here that mass spectrometry can excel.
4. ESI–IMS–MS as a separative technique for characterizing
amyloidogenic conformers
ESI–IMS–MS is particularly useful in the study of amyloid ﬁbril for-
mation, being capable of separating co-populated multiple conforma-
tions of the same protein monomer with the same m/z ratio but that
differ in physical size or shape. This is a key issue in amyloid ﬁbril for-
mation as protein unfolding or mis-folding frequently precedes ﬁbril
formation and hence the conformational properties of the protein
require characterization. Numerous studies have shown that the
electrospray process can conserve protein's solution-phase characteris-
tics in the gas-phase and, using ESI–MS alone, it is possible to estimate
the population of different conformational states by interpretation of
the protein's charge state distribution [4,52–55]. Unfolded conforma-
tions expose more ionizable sites and thus give rise to higher charge
states during ESI than more folded, and therefore more compact,
conformations of the same protein. Using this approach, Gaussian
Fig. 3. IMS–MS interrogation of the assembly pathway of the prion protein fragment
106–126 (PrP106–126) [80]. (a) Ion mobility traces for the +2 charge state monomer
ions of PrP106–126 (labeled “Normal”) showing the presence of Species A (CCS=371 Å2)
together with Species B, an expanded β-sheet conformation with a CCS of 466 Å2, at early
time-points. Species B is absent in the “Control” sample, a non-amyloidogenic peptide of
the same amino acid composition but with a scrambled sequence (CCS=391 Å2). The pop-
ulation of expanded conformers in the “Normal” PrP106–126 decreases over time as species
with drift times of 390 μs (CCS=302 Å2) and 425 μs (CCS=347 Å2) appear (see arrows).
These peaks are presumed to be oligomeric as the CCS values are too small to belong to a
monomeric conformer with +2 charges. (b) Schematic showing the proposed mechanism
of PrP106–126oligomer formation involving the assembly of Species A andSpecies B into or-
dered small aggregates.
Reprinted with permission from M. Grabenauer, C. Wu, P. Soto, J.-E. Shea, M.T. Bowers,
Oligomers of the Prion protein fragment 106–126 are likely assembled from β-hairpins
in solution, and methionine oxidation inhibits assembly without altering the peptide's
monomeric conformation, J. Am. Chem. Soc., 132 (2009) 532–539 [80].
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protein's m/z spectrum to estimate the number of conformers (or
conformeric families) present [4,7,52,53,55]. For example, in the case
of α-synuclein, an intrinsically unstructured, highly amyloidogenic,
14.5 kDa protein associated with Parkinson's disease, multiple distinct
conformations of the protein monomer have been identiﬁed using
ESI–MS [53,54]. Recently, an amyloidogenic auto-proteolysis product
of α-synuclein, consisting of residues 70–140, has been identiﬁed
using ESI–IMS–MS [56]. This experiment involved separating the
degraded α-synuclein sample from intact α-synuclein in the IMS cell,
allowing the two species to be characterized individually.
Fitting charge state distributions to ESI–MS m/z spectra provides in-
formation about the number of distinct conformations present and their
relative populations, but often the charge state ions of the various con-
formers overlap and also this approach does not allow further, individ-
ual interrogation of these species. By contrast, using ESI–IMS–MS,
monomeric conformers with different CCSs can be fully separated and
further information gained on each species following interpretation of
their CCS. Early experiments utilising travelling-wave IMS–MS to identi-
fy amyloid precursor states were performed on beta-2 microglobulin
(β2m), a 99-residue, seven β-stranded protein [57]. β2m ﬁbril formation
is of particular interest, as incubating wild-type human β2m alone at
near-physiological pH in vitro is insufﬁcient to cause aggregation
[58,59]. However, in vivo β2m is the main component of ﬁbrils deposit-
ed in patients undergoing dialysis due to renal failure. These ﬁbrils are
associated with the disease dialysis-related amyloidosis (DRA) [60,61].
It is only by modifying the protein [38,59,62–65], lowering the pH
[66,67] or incubating the protein with certain additives [68–72] that
ﬁbril formation is able to proceed. In the experiments performed by
Smith et al., low pH was used to initiate ﬁbril formation [57]. Under
these conditions, three different conformeric families of the protein
monomer were separated using ESI–IMS–MS: compact, partially com-
pact and expanded conformations [57], consistent with previous results
obtained by ﬁtting the charge state distributions [52]. Despite the dena-
turing conditions used, the compact conformer has a CCS value that
correlates well with that of the native structure of β2m [28], as charac-
terized by both NMR [38,73] and X-ray diffraction [74]. These results
show that residual interactions are maintained within the structure of
β2m, even under harsh solution conditions, and it has been demonstrat-
ed that this structure is necessary for ﬁbril formation to occur [75,76].
Once the CCS of a protein conformer has been estimated it is
possible to use coarse-grain modelling or molecular dynamics simula-
tions to reveal potential structures consistent with the ESI–IMS–MS
data obtained. This approach has been used in the analysis of the
amyloidogenic proteins α-synuclein [77], Aβ [78], islet amyloid poly-
peptide (IAPP) [79], and a short peptide associated with prion aggre-
gation [80]. In the case of IAPP ﬁbril formation, which is associated in
vivo with type II diabetes [81], the 37-residue peptide monomer un-
dergoes a distinct change in conformation which has been identiﬁed
using IMS–MS [79]. Although human IAPP is able to form ﬁbrils sponta-
neously in vitro at pH 7, rat IAPP (which differs by only six residues in the
core amyloidogenic region of the peptide sequence) is not amyloidogenic
under the same conditions [82]. Therefore, the rat protein is ideal to use
as a control [83]. Using ESI–IMS–MS, human IAPPwas shown to populate
a more expanded conformation than its rat counterpart [79]. Molecular
dynamics simulations revealed that the expanded conformation of
human IAPP is likely populated by a β-hairpin structure, whereas the
more compact conformation occupied by rat IAPP can be attributed to a
more helical conformation. These results are in good agreement with
NMR data that identiﬁed the initiation of human IAPP ﬁbril formation
fromaβ-hairpin intermediate [84]. These studies testify to the use ofmo-
lecular dynamics simulations restrained with CCS values determined
from IMS–MS measurements to analyse the early stages of protein
self-assembly into amyloid. A β-hairpin structure for the human IAPP
dimer has also been suggested by combining IMS–MS with molecular
dynamics simulation; CCS values were consistent with a speciescontaining two β-hairpin IAPPmonomers bound side-to-side [85]. In an-
other example using this approach, the prion fragment 106–126was also
shown to adopt an expanded conformation, with molecular dynamics
simulations again suggesting a β-hairpin structure [80]. Importantly,
this conformation was absent in control samples (Fig. 3). Over time, the
population of the β-hairpin-like species decreased, while ions corre-
sponding to a second peak in the ion mobility spectrum increased. The
latter specieswas thought to be populated by oligomers, with an increase
in β-sheet structure, consistent with circular dichroism analysis.
In summary, although still in infancy compared with other struc-
tural methods, IMS–MS is now accepted as a powerful method to
determine conformational properties of unfolded and partially folded
species, as well as natively folded proteins. In the context of amyloid
formation, this is of signiﬁcance as the onset of ﬁbril formation can be
induced by rarely-populated conformers of highly dynamic proteins.
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intermediates in amyloid assembly
In addition to providing insights into the structures of protein
monomers, CCS values can also be assigned to larger, non-covalently
bound biomolecular species [8,17,29]. A major challenge when
analysing the pathway of amyloid ﬁbril formation is identifying and
characterizing transient oligomeric intermediates en route to larger
aggregates and ﬁbrils (Fig. 2e). As these early stages in amyloid forma-
tion are highly heterogeneous with multiple, rapidly inter-converting
species being co-populated in solution, this presents a signiﬁcant
challenge. In this scenario mass spectrometry is an ideal technique:
ESI–MS has been shown to be capable of preserving non-covalently
bound species [5,6] and the high sensitivity ofmodernmass spectrom-
eters enables detection of species present even at femtomolar concen-
trations within complex mixtures. Whereas ion mobility separation
of protein monomers is primarily dictated by the individual shapes
of the protein's conformers, the effect of charge is more predominant
when separating oligomeric species arising from the same protein
monomer. For example, when singly charged monomer, doubly
charged dimer and triply charged trimer ions all populate the same
m/z, the trimer is more likely to have a shorter drift time than the
monomer, despite the trimer having a larger CCS, due to the effect of
multiple charging (Fig. 1). This is an important factor to take into
account when assigning oligomeric species. However, because the
drift time depends on both CCS and charge, predicting the arrival
time of an ion is complex and analysis of a charge state series of
ions is needed to make a clear assignment for each individual species
[57].
One advantage that mass spectrometry possesses over other bio-
physical techniques is its ability to distinguish between individual
oligomeric states within highly heterogeneous systems. By contrast,
techniques such as light-scattering or ﬂuorescence reveal only infor-
mation about the average properties of the species populated. Single
molecule ﬂuorescence, especially when combined with two colour
coincidence detection, can separate different oligomeric species but
requires them to have signiﬁcant differences in their diffusion times
[51,86,87], and even so, this technique has a resolution much poorer
than that of IMS–MS. Early ESI–MS experiments have identiﬁed
high-order oligomeric species for several different amyloid systems
[88,89]. In these examples, oligomer size was determined using m/z
alone. This approach relies on identifying charge states based on the
observed C13 isotope spacing [90], or identifying oligomer size
based on unique, odd numbered charge states [88,89]. However, in
some cases it is impossible to establish whether a particular oligomer
is present using ESI–MS alone, especially where the ions of a particu-
lar species have m/z values that all coincide with those from other
oligomers. Further separation is required to conﬁrm the repertoire
of oligomers populated during ﬁbril formation. Using ESI–IMS–MS
this is possible [80,85,91–95]; ions with m/z values that have contri-
butions from multiple different oligomeric states can be separated
and investigated in terms of structure and dynamics due to differ-
ences in their mobility as they travel through the IMS drift cell.
The assemblies of Aβ40 and Aβ42 have been characterized exten-
sively using ESI–IMS–MS [78,90,91,95,96]. The peptide Aβ is cleaved
from the amyloid precursor protein (APP), an event which produces
predominantly either a 40- or 42-residue peptide (Aβ40 and Aβ42)
[49]. Both peptides are capable of assembling into amyloid ﬁbrils in
vivo, although Aβ42 is the more aggregation prone [97]. Fibrils of
Aβ40/42 deposit in the brains of Alzheimer's sufferers, causing the
cell death associated with memory loss [98,99]. It has been suggested
that the variation in amyloidogenicity between Aβ40 and Aβ42 could
result from differences in their oligomerization pathways [91,100].
Different oligomers of each peptide, identiﬁed using cross-linking
and native polyacrylamide gel electrophoresis [100], have been char-
acterized using conventional IMS–MS [91]. Using this approach, Aβ42was found to form both a tetramer and a hexamer. The hexamer was
shown to be capable of stacking with a second hexamer to form a
2-ring dodecamer, which then proceeded to form ﬁbrils. In contrast,
under the same conditions Aβ40 was found to form only a tetramer
thatwasmore compact than theAβ42 tetramer. From these data, the au-
thors suggested that the aggregation pathways of Aβ40 and Aβ42
diverge, resulting in different kinetics and assembly mechanisms for
each sequence, commensurate with their different amyloidogenicities.
The Aβ40/42 results thus described were obtained using negative
mode ESI–MS. More recent experiments using positive mode ESI with
travelling-wave IMS–MS produced different results [90]. In this case,
an array of oligomeric species from monomer to 13-mer inclusive,
together with higher order species, were observed for Aβ40 [90]
(Fig. 4). The discrepancies between the two datasets could arise for a
number of different reasons, including the differences in ionization
mode (whereby the charges imposed could inﬂuence the structure of
oligomers), instrument design and variations in sample preparation.
All of these variables may lead to differences in the oligomer species
detected, especially as it has been reported that several different
polymorphs of Aβ40 exist [101]. However, analyses of α-synuclein
have shown that the ionization mode polarity has no effect on the dis-
tribution of monomeric conformers of this protein [54,77,102], nor on
the distribution of monomer and dimer species formed [53,103].
The Aβ40 study above not only demonstrates the utility of
travelling-wave IMS–MS to separate a multitude of Aβ40 oligomers, but
also highlights the ability of this technique to characterize different
conformations of individual oligomeric state [90]. This study used a
second-generation travelling-wave IMS–MS instrument with improved
m/z resolution, which allowed charge states to be assigned for highly-
charged ions using their C13 isotope patterns (Fig. 4).
Using ESI and travelling-wave IMS–MS, oligomeric species have been
detected during β2m ﬁbril formation. β2m is able to form ﬁbrils of two
distinct morphologies at low pH (Fig. 5a) in vitro [104]. ESI–IMS–MS
has been used as a tool to identify the different populations of oligomers
formed on each assembly route and to discern where the two different
assembly pathways diverge [94]. At pH 2.5 and in low ionic strength
buffer, β2m forms ﬁbrils in vitro that have a long-straight, unbranched
morphology typical of ex vivo amyloid [67,105]. By contrast, at pH 3.6
and with increased ionic strength, β2m forms ﬁbrils of a different, less
well-ordered morphology, termed “worm-like”, due to their short,
curved appearance (Fig. 5a) [89,104,106]. ESI–IMS–MS revealed differ-
ences in the distribution of oligomers formed under each of these condi-
tions: whereas oligomers up to tetramer in size, but no larger species, are
populated during the formation of long-straight ﬁbrils [93], high-order
oligomers up to at least 14-mer are observed during worm-like ﬁbril for-
mation [94] (Fig. 5b, c). These results correlate well with earlier ESI–MS
experiments, whereby oligomeric species up to 20-mer in size were
identiﬁed under conditions that result in worm-like ﬁbrils, while species
up to only tetramer were observed under conditions in which long-
straight ﬁbrils form [89]. Through comparison of the CCSs of species
common to both aggregation mechanisms, the point of divergence of
the two pathways has been identiﬁed [94]. Although the CCS values for
the monomer, dimer and trimer are comparable under both sets of con-
ditions, β2m populates an additional, more compact tetramer under con-
ditions that lead to the formation of worm-like ﬁbrils (Fig. 5c). This
compact tetramer is thought to oligomerize further by monomer addi-
tion, resulting eventually in worm-like ﬁbril formation via an extensive
series of oligomers differing in mass by a single monomer (Fig. 5a). By
contrast, at pH 2.5 the observation of species only up to a tetramer in
size is consistent with a nucleated mechanism for the formation of
long-straight ﬁbrils via a hexameric nucleus (Fig. 5a) [43]. Estimation
of the CCSs of oligomers formed during the assembly of β2m monomers
into ﬁbrils has yielded further insights into how these ﬁbrils form. The
β2m oligomers are consistent with the population of a stacked confor-
mation, much extended when compared with a globular protein of a
similar mass [93].
Fig. 4. Aβ40 oligomers separated and identiﬁed by travelling-wave IMS–MS [90]. (a) Three-dimensional IMS–MS spectrum of Aβ40 for the m/z 2164–2168 region containing
overlapping charge states arising from monomeric (MON), dimeric (DIM), trimeric (TRI) and tetrameric (TET) Aβ40. m/z values are shown on the vertical axis and ion mobility
drift times (ms) on the horizontal axis. The signal amplitude is colour-coded, increasing from purple (low intensity) to bright yellow (high intensity). The insets show the isotopic
patterns of the IMS-separated +2 monomer ions, +4 dimer ions, +6 trimer ions and +8 tetramer ions, all of the same m/z value, from which the oligomers can be identiﬁed
unambiguously. Note there are two trimers with different drift-times, the one with the higher mobility and shorter drift time being the more compact of the two. (b) Summary
of the oligomer composition of the m/z 2164–2168 region following assignment of each species based on its C13 isotope distribution, demonstrating the presence of two different
Aβ40 trimers and showing clearly the drift times (ms) of each oligomeric state.
Reprinted with permission from M. Kłoniecki, A. Jabłonowska, J. Poznański, J. Langridge, C. Hughes, I. Campuzano, K. Giles, M. Dadlez, Ion mobility separation coupled with MS
detects two structural states of Alzheimer's disease Aβ1–40 peptide oligomers, J. Mol. Biol., 407 (2011) 110–124 [90].
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during the self-assembly of the small peptides NNQQNY, VEALYL
and SSTNVG [107], highly-amyloidogenic sequences from the yeast
prion protein Sup 35, human insulin, and IAPP, respectively. Aggrega-
tion proceeds rapidly in vitro for each of these short sequences,
occurring via stacked assemblies of high-order oligomers that populate
extended, ﬁbril-like conformers rather than compact or globularassemblies commencing even as early as dimeric species (Fig. 6).
These extended oligomers differ dramatically from the oligomers ob-
served for the peptide YGGFL, a non-amyloidogenic control sequence.
Interestingly, the amyloidogenic peptidesNNQQNYand SSTNVGdisplay
initially an isotropic distribution of compact oligomers, but these
species divert to extended conformations at the octamer or 11-mer
subunit, respectively. By contrast, oligomers of VEALYL populate only
Fig. 5. In vitro ﬁbril formation from β2-microglobulin (β2m) monitored in real-time by
travelling-wave IMS–MS. (a) Schematic showing two assembly pathways which diverge to
formworm-likeﬁbrils (non-nucleatedassembly) or long-straightﬁbrils (nucleated assembly
following a lag-phase). (b) Three-dimensional IMS–MSspectrum(m/z 6000–10,000) show-
ing β2m oligomers 1 min into ﬁbril assembly in 100 mM ammonium formate buffer
(pH 2.5), which triggers the formation of long-straight ﬁbrils. (c) Three-dimensional
IMS–MS spectrum (m/z 6000–10,000) showing β2m oligomers 1 min into ﬁbril assembly
in 400 mM ammonium formate buffer (pH 2.5) which triggers the formation of worm-
like ﬁbrils. In both (b) and (c) the numbers above each peak indicate the oligomer size.
The +7 and +8 charge state ions of the tetramer are highlighted (yellow ovals) in each
case to show the increase in their population with increasing ionic strength denoting the
point at which the pathways of assembly are thought to diverge. Insets show atomic
force microscopy images of the ﬁbrils formed at the end-points of assembly in each case;
the scale bars represent 200 nm.
The original data were published in D.P. Smith, L.A. Woods, S.E. Radford, A.E. Ash-
croft, Structure and dynamics of oligomeric intermediates in beta2-microglobulin
self-assembly, Biophys. J., (2011) 101, 1238–1247 [94].
1263L.A. Woods et al. / Biochimica et Biophysica Acta 1834 (2013) 1257–1268an extended conformation initially. These extended oligomers are
thought to have β-sheet content postulated to be a prerequisite for
amyloid formation. Consistent with these observations, assembly via
compact or extended conformers has been predicted using all-atom
computer simulations [44], the ﬂux along each pathway depending on
the peptide sequence, hydrophobicity and β-sheet propensity.6. ESI–IMS–MS can be used to unravel themechanism of inhibition
of ﬁbril assembly by small molecules
Recently there has been an increasing interest in applying IMS–MS to
study small-molecule inhibitors of amyloid systems [95,102,108,109].While ESI–MS has been used to detect protein-ligand interactions soon
after the development of the technique [6,110,111], it was not until
over a decade later that this approach was ﬁrst used to probe inhibitors
of amyloid systems [112–114]. One of the earliest studies in this areawas
performed by Robinson and co-workers who used ESI–MS to identify in-
hibitors of transthyretin (TTR) amyloidosis [113]. TTR is active in the
serum and cerebroserum as a homotetramer, whereby its function is to
transport vitamin A or the hormone thyroxine, respectively. However,
upon dissociation from its tetrameric state, TTR mis-folds and aggregates
into amyloid ﬁbrils. One strategy for preventing TTR amyloidosis is by
stabilisation of the native tetramer by ligand binding [113]. These studies
showed clear evidence for TTR tetramer stabilisation via binding of
ligands that target the thyroxine binding site. Subsequent evolution of
these ligands has led to the ﬁrst small molecule therapeutic for an amy-
loid disease, tafamidis [115].
More recent applications of ESI–MS have extended these early anal-
yses, introducing ion mobility separation to determine the mechanism
of inhibition when the starting conformer is not a folded state. This
approach has now been applied to a variety of such amyloid systems,
including Aβ42, α-synuclein, and β2m at low pH [95,102,108,109]. In
these cases, ESI–IMS–MSwas used to separate monomers and different
oligomers, and to detect inhibitor binding to speciﬁc monomeric
conformations and oligomeric intermediates. One such study used
ESI–IMS–MS to investigate the mechanism of inhibition of β2m aggre-
gation into long-straight ﬁbrils at pH 2.5 [108]. In this work, rifamycin
SV, an antibiotic from the family of rifamycins (Fig. 7), was shown to be
active against β2m ﬁbril formation. Interestingly, rifamycin SV also pre-
vents Aβ40/42 ﬁbrillation [116]. Rifampicin, a similarly structured mac-
rocyclic antibiotic also of the rifamycin family, has been shown to be
active against aggregation of Aβ andα-synuclein [117,118], but was in-
effective when incubated with IAPP or β2m [108,119]. These results
demonstrate that the interaction of rifamycin SV with these proteins
is speciﬁc, as minor differences in the structure of the small molecule
remove its ability to inhibit. Similarly, rifaximin, another antibiotic
from the rifamycin family, has been shown to be inactive against β2m
ﬁbril formation at low pH [108] (Fig. 7). Inactive small molecules that
have similar structures to potential inhibitors, and therefore similar
electrospray ionization efﬁciency, are ideal to use as a control for
non-speciﬁc binding when analysing ligand binding using ESI–MS
[120,121]. Binding of rifaximin to β2m therefore provides an appropri-
ate control in the determination of the mechanism of action of
rifamycin SV. Using ESI-IMS-MS to separate the different monomeric
conformers populated by β2m at pH 2.5 (Fig. 7a), rifamycin SV was
found to bind to all three conformations i.e. compact, partially compact,
and extended conformers (Fig. 7b). By contrast, rifaximin binds only to
the most compact conformation (Fig. 7c). Previous analyses of β2m at
acidic pH had indicated that the compact conformation has a CCS
that correlates well with that expected for native-like β2m [28,93].
Given that ﬁbril formation is not inhibited, but the lag-time of ﬁbril for-
mation is extended in the presence of rifaximin, these data enable the
role of different conformers in ﬁbril formation to be deduced (Fig. 8).
Accordingly, the most compact conformer is thought not to be neces-
sary for the amyloidogenic pathway. By contrast, the unfolded and par-
tially folded conformers are necessary for assembly into the ﬁbrillar
form under these conditions.
In a similar set of experiments, Z-Phe-Ala-diazomethylketone
(PADK), a known inhibitor of Aβ42 aggregation [122], was analysed by
Bowers and coworkers to determine whether any interaction occurs
between PADK and Aβ42, as well as the effect of the inhibitor on the
well-characterized oligomerisation pathway described previously
[91,109]. The results obtained were reminiscent of the effect observed
between rifamycin SV and β2m: IMS–MS revealed that PADK binds to
Aβ42 monomer and oligomers, the effect of which is to cause the disso-
ciation of high-order oligomers. Thus, PADK binding thwarts Aβ42
aggregation by preventing the formation of higher order oligomers
and by inducing the dissociation of any previously-formed dodecamers.
Fig. 6. The in vitro self-assembly of peptide monomers into mature, insoluble β-sheet ﬁbrils via an intermediate phase of soluble oligomers monitored by IMS–MS [107].
Self-assembly starts at the folded monomer (n=1, left) and proceeds to soluble peptide assemblies of increasing mass (n=2, 4, 7, and 10). Soluble peptide oligomers with identical
mass (i.e. the same number of monomer units, n) can assume different conformations such as globular (blue structure, bottom) or β-strand conformations (yellow arrows, top)
with different CCS. Successively mass-extracting a speciﬁc aggregation state from the solution-phase distribution and subsequent determination of its CCS reveals the
self-assembly pathway taking place in solution (large, pale blue arrow). A pronounced transition of soluble oligomers (horizontal axis) from globular conformations into
β-strand structures occurs during this phase. The oligomer size at which the divergence from compact to extended conformers occurs differs for peptides of different sequences.
Reprinted with permission from C. Bleiholder, N.F. Dupuis, T. Wyttenbach, M.T. Bowers, Ionmobility–mass spectrometry reveals a conformational conversion from random assembly
to β-sheet in amyloid ﬁbril formation, Nat. Chem., 3 (2011) 172–177 [107].
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monomeric α-synuclein has also been assessed by ESI–IMS–MS in the
presence of the inhibitor epigallocatechin gallate (EGCG), a polyphenolicFig. 7. Small molecule inhibition of β2m ﬁbril formation in vitro [108]. Three-dimensional IM
and (c) β2m with equimolar rifaximin added. The numbers adjacent to the peaks (e.g. +5)
protein conformers are encircled with dashed lines and labeled individually: compact, par
number of ligand molecules bound to each charge state of β2m in the different spectra (r
and hence all conformers of monomeric β2m, thereby inhibiting ﬁbril formation. (c) Rifaxi
expanded conformers, and does not inhibit ﬁbril formation. The summed m/z spectrum for
of rifamycin SV and rifaximin are positioned below the relevant spectra in (b) and (c), resp
Reprinted with permission from L.A. Woods, G.W. Platt, A.L. Hellewell, E.W. Hewitt, S.W. Ho
an amyloid-forming protein, Nat. Chem. Biol., 7 (2011) 730–739 [108].antioxidant abundant in green tea that has also been shown to be effec-
tive against Aβ aggregation [102]. The inhibition of ﬁbril formation
caused by EGCG has been well characterized, the small molecule beingS–MS spectra of (a) β2m monomer alone; (b) β2m with equimolar rifamycin SV added;
indicate the charge state carried by those ions, and charge states belonging to the same
tially compact, and expanded. The ﬁlled coloured circles on the spectra represent the
ed for rifamycin SV, green for rifaximin). (b) Rifamycin SV binds to all charge states
min binds only to the compact protein conformer but not the partially compact or the
β2m (11,860 Da) alone is shown on the left-hand side of (a). The molecular structures
ectively.
mans, A.E. Ashcroft, S.E. Radford, Ligand binding to distinct states diverts aggregation of
Fig. 8. Schematic showing small molecule inhibition of β2m ﬁbril formation in vitro [108]. The initial protein equilibrium consists of a mixture of monomeric protein conformers
(compact, partially compact, and extended) together with protein dimer and some higher order oligomers. Rifamycin SV binds to the compact, partially compact and expanded
conformers of β2m, inhibiting ﬁbril formation and diverting assembly to spherical aggregates. Rifaximin, however, binds only to the compact conformer of β2m, but not to the
partially compact or the extended conformers, and does not prevent β2m from undergoing self-aggregation to form ﬁbrils.
Reprinted with permission from L.A. Woods, G.W. Platt, A.L. Hellewell, E.W. Hewitt, S.W. Homans, A.E. Ashcroft, S.E. Radford, Ligand binding to distinct states diverts aggregation of
an amyloid-forming protein, Nat. Chem. Biol., 7 (2011) 730–739 [108].
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[123,124]. Pukala and co-workers detected a compaction of the
amyloidogenic A53T mutant of α-synuclein preceding ﬁbril formation
using ESI–IMS–MS [102]. Thismutant protein is associatedwith familial
Parkinson's disease and had been analysed previously by others using
ESI–IMS–MS [125] and shown to populate a more compact species
than wild-type α-synuclein; the conclusion being that this compact
amyloidogenic state is associated with increased amyloidogenicity.
However, upon addition of the inhibitor EGCG to A53T α-synuclein,
the conformational change to the compact, amyloidogenic state was
prevented, and instead binding of EGCG to A53T resulted in the forma-
tion of a ligand-bound off-pathway conformer [102]. Interestingly, the
effect of the small molecule spermine, a compound that accelerates
ﬁbril formation of A53T α-synuclein, has also been investigated using
ESI–IMS–MS [125]. Spermine was found to bind to α-synuclein, initiat-
ing the formation of the compact state of α-synuclein, thereby increas-
ing amyloidogenicity.
Together, these recent experiments demonstrate the signiﬁcant
potential of IMS–MS to identify the mechanism of action of small mol-
ecules that modulate the course of ﬁbril assembly. The information
gained is powerful, enabling speciﬁc protein conformers within anarray of unfolded species capable of ligand binding to be identiﬁed. In
addition, these studies permit the roles of different conformers in the
amyloid assembly route to be deﬁned. While structure-based drug de-
sign has revolutionized the potentials for therapeutic intervention of
native proteins, IMS–MS offers new opportunities for developing and
characterizing small molecules able to bind and modulate assembly
of highly dynamic, non-native states.
7. Outlook and future potentials of IMS–MS in amyloid research
Investigating the mechanism of amyloid ﬁbril formation using mass
spectrometry has progressed signiﬁcantly in the past decade, yet many
questions remain to be answered. These enigmas include deﬁning how
ﬁbril formation proceeds and the precise protein/peptide interfaces that
are involved in oligomerization. Further insights into the structure of
oligomers formed during amyloid assembly, and also by dissociation
from ﬁbril ends, are key to evaluating and preventing the toxic effects
of amyloid formation and deposition. Currently, a number of chemical
techniques are being exploited in conjunction with MS and IMS–MS
with the aim of providing complementary information to that available
using IMS–MS alone. These include hydrogen deuterium exchange–
1266 L.A. Woods et al. / Biochimica et Biophysica Acta 1834 (2013) 1257–1268mass spectrometry (HDX–MS), cross-linking, oxidative labeling and
chemical modiﬁcation [11,126–130]. For example, pulsed-labeling
HDX–MS has revealed how a structural rearrangement of oligomers
precedes ﬁbril formation of an SH3 domain [45], has produced insights
into the β-hairpin arrangement of Aβ40 and Aβ42 oligomers [131] and
has shown how Aβ40/42 ﬁbrils exist in equilibrium with Aβ monomer
in solution [132]. The use of IMS–MS integrated with these analyses
would allow modelling of the possible conformations of each of
these oligomers. Covalent modiﬁcation of oligomers can also be used
in conjunction with IMS–MS to give more depth to these analyses.
Oligomers can be cross-linked by introducing photo-reactive substitu-
ents into the protein/peptide sequence or by using other photo-
oxidation strategies [133–135]. Activation of these substituents initi-
ates covalent bond formation, thus trapping the intermediate species.
These cross-linked species can then be analysed using IMS–MS to yield
information about their shape, the site of the cross-link, and therefore
the oligomerization interface. Alternatively, oxidative foot-printing
can be used to label the amino acid side chains of proteins [126,127],
revealing sites that are protected during oligomerization. Further,
developments in IMS–MS instrumentation has enabled site-speciﬁc
information about protein conformation and binding interfaces to be
revealed using gas-phase HDX labeling [136,137]. For example, HDX
of labile amino acid side-chain protons takes place within the mass
spectrometer following the ionization process, through collisions
with deuterated ammonia. Electron transfer dissociation can then be
used for top-down sequencing [138,139] of the intact protein to reveal
site-speciﬁc information about the location of exposed side-chains.
In summary, the last decade has witnessed enhancements in ESI–MS
by means of integration with IMS for the analysis of the structure, as-
sembly and dynamics of complex macromolecular systems including
amyloid ﬁbril formation. The separating power of ESI–IMS–MS, together
with the potential of chemical labeling, HDX and other chemical strate-
gies will ensure that ESI–IMS–MS will continue to play a major role in
our quest to determine the molecular mechanisms of assembly of
peptides and proteins into amyloid ﬁbrils. Perhaps most excitingly,
using ESI–IMS–MS to facilitate the design, development and analysis
of protein–ligand interactions in amyloid formation offers new opportu-
nities to devise novel therapeutic strategies to inhibit ﬁbril formation
and/or the population of cytotoxic species.Acknowledgements
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